Gemigliptin: Newer Promising Gliptin for Type 2 Diabetes Mellitus

The dipeptidyl peptidase-4 (DPP-4) inhibitors have facilitated the management of type 2 diabetes mellitus (T2DM) owing to their superior efficacy and safety with low incidence of adverse effects. Gemigliptin is a new member of this family of drugs, and studies have revealed certain advantages of gem...

Descripción completa

Detalles Bibliográficos
Autores principales: Gutch, Manish, Joshi, Abhay, Kumar, Sukriti, Agarwal, Avinash, Pahan, Rajendra Kumar, Razi, Syed Mohd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2017
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5729681/
https://www.ncbi.nlm.nih.gov/pubmed/29285456
http://dx.doi.org/10.4103/ijem.IJEM_20_17
_version_ 1783286236499148800
author Gutch, Manish
Joshi, Abhay
Kumar, Sukriti
Agarwal, Avinash
Pahan, Rajendra Kumar
Razi, Syed Mohd
author_facet Gutch, Manish
Joshi, Abhay
Kumar, Sukriti
Agarwal, Avinash
Pahan, Rajendra Kumar
Razi, Syed Mohd
author_sort Gutch, Manish
collection PubMed
description The dipeptidyl peptidase-4 (DPP-4) inhibitors have facilitated the management of type 2 diabetes mellitus (T2DM) owing to their superior efficacy and safety with low incidence of adverse effects. Gemigliptin is a new member of this family of drugs, and studies have revealed certain advantages of gemigliptin use compared to its previous congeners. Besides, this drug has also been studied for the treatment of T2DM as monotherapy, in combination with metformin or other oral antidiabetic drugs and in T2DM with moderate-to-severe renal failure. In this review, we explore the published data highlighting the pharmacology, efficacy, and safety of gemigliptin along with its recommendations for use in patients with T2DM.
format Online
Article
Text
id pubmed-5729681
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-57296812017-12-28 Gemigliptin: Newer Promising Gliptin for Type 2 Diabetes Mellitus Gutch, Manish Joshi, Abhay Kumar, Sukriti Agarwal, Avinash Pahan, Rajendra Kumar Razi, Syed Mohd Indian J Endocrinol Metab Review Article The dipeptidyl peptidase-4 (DPP-4) inhibitors have facilitated the management of type 2 diabetes mellitus (T2DM) owing to their superior efficacy and safety with low incidence of adverse effects. Gemigliptin is a new member of this family of drugs, and studies have revealed certain advantages of gemigliptin use compared to its previous congeners. Besides, this drug has also been studied for the treatment of T2DM as monotherapy, in combination with metformin or other oral antidiabetic drugs and in T2DM with moderate-to-severe renal failure. In this review, we explore the published data highlighting the pharmacology, efficacy, and safety of gemigliptin along with its recommendations for use in patients with T2DM. Medknow Publications & Media Pvt Ltd 2017 /pmc/articles/PMC5729681/ /pubmed/29285456 http://dx.doi.org/10.4103/ijem.IJEM_20_17 Text en Copyright: © 2017 Indian Journal of Endocrinology and Metabolism http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Review Article
Gutch, Manish
Joshi, Abhay
Kumar, Sukriti
Agarwal, Avinash
Pahan, Rajendra Kumar
Razi, Syed Mohd
Gemigliptin: Newer Promising Gliptin for Type 2 Diabetes Mellitus
title Gemigliptin: Newer Promising Gliptin for Type 2 Diabetes Mellitus
title_full Gemigliptin: Newer Promising Gliptin for Type 2 Diabetes Mellitus
title_fullStr Gemigliptin: Newer Promising Gliptin for Type 2 Diabetes Mellitus
title_full_unstemmed Gemigliptin: Newer Promising Gliptin for Type 2 Diabetes Mellitus
title_short Gemigliptin: Newer Promising Gliptin for Type 2 Diabetes Mellitus
title_sort gemigliptin: newer promising gliptin for type 2 diabetes mellitus
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5729681/
https://www.ncbi.nlm.nih.gov/pubmed/29285456
http://dx.doi.org/10.4103/ijem.IJEM_20_17
work_keys_str_mv AT gutchmanish gemigliptinnewerpromisinggliptinfortype2diabetesmellitus
AT joshiabhay gemigliptinnewerpromisinggliptinfortype2diabetesmellitus
AT kumarsukriti gemigliptinnewerpromisinggliptinfortype2diabetesmellitus
AT agarwalavinash gemigliptinnewerpromisinggliptinfortype2diabetesmellitus
AT pahanrajendrakumar gemigliptinnewerpromisinggliptinfortype2diabetesmellitus
AT razisyedmohd gemigliptinnewerpromisinggliptinfortype2diabetesmellitus

Ejemplares similares